Recursion Pharmaceuticals (RXRX.US) experienced a sharp decline in premarket trading on Wednesday. At the time of writing, the stock had fallen more than 13% to $3.46. The drop follows the disclosure in a 13F filing submitted by NVIDIA (NVDA.US) to the U.S. Securities and Exchange Commission, which revealed that the company completely exited its position in Recursion Pharmaceuticals during the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments